No Carolina / NY / Florida
Ph: 561.316.3330

No Carolina | NY | Florida

STALIF M FLX 3D-Printed ALIF Device Listed by SPINE Market Group as the Top ALIF 3D-printed Cage

Editor: What To Know

  • STALIF implants uniquely provide compressive fixation at the fusion site, pulling the vertebral bodies onto the implant and graft material to enhance opportunities for fusion in line with Wolff’s Law of Bone Healing.
  • STALIF M FLX is the latest evolution of the STALIF portfolio, and continues our heritage in advancing the stand-alone market founded over 30 years ago,”.
  • STALIF M FLX implants have been engineered based on the STALIF® design which has over 30 years of proven clinical history and has helped thousands of patients regain their lives—including the world’s winningest athlete, Tiger Woods.

February 11, 2021

STALIF M FLX platform represents the latest material advancement offered by Centinel Spine.

FLX implants are 3D-printed porous titanium, meticulously engineered down to the cellular unit level to mimic bone. The FLX family of implants boasts equivalent subsidence performance to PEEK; contains a proprietary, interconnected FUSE-THRU lattice with a structure similar to bone; and has an optimized mechanical environment to reduce stress shielding, enable fusion assessment, and support bony in-growth, on-growth, and thru-growth.

STALIF M FLX implants have been engineered based on the STALIF® design which has over 30 years of proven clinical history and has helped thousands of patients regain their lives—including the world’s winningest athlete, Tiger Woods. STALIF implants uniquely provide compressive fixation at the fusion site, pulling the vertebral bodies onto the implant and graft material to enhance opportunities for fusion in line with Wolff’s Law of Bone Healing.

Centinel Spine is proud that the STALIF M FLX device has been recognized as the top ALIF 3D-printed cage,” stated Centinel Spine CEO Steve Murray. “As a company, we remain dedicated to continued product quality, innovation, and furthering clinical evidence. STALIF M FLX is the latest evolution of the STALIF portfolio, and continues our heritage in advancing the stand-alone market founded over 30 years ago,” concluded Murray.

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

Recent News

VeraClinic: Pioneering Personal Transformation Through Hair Transplantation and Cosmetic Surgery in Turkey

As a testament to Turkey's legacy in the world of aesthetic medicine, VeraClinic invites you to discover the transformative power of our hair transplantation and cosmetic surgery services.

CV Societies Propel Plans Forward for a New Board of Cardiovascular Medicine

“The open comment period is the time for cardiovascular physicians, allies in other medical specialties, patients, and others to make their voices heard on why an independent CV Board is the best path for cardiologists to stay up-to-date on best practices and evidence-based care, ensuring patients receive the best possible care,” said Jeffrey Kuvin, MD, president of the proposed Board’s new Board of Directors. “The field of cardiovascular medicine has evolved dramatically over the past few decades; now is the right time to develop an independent cardiovascular Board.”

Hyundai Bioscience Announces Clinical Development Plan for Niclosamide-based Metabolic Anticancer Drug Targeting P53 Mutation Cancer

Sang-ki Oh, CEO of Hyundai Bioscience, stated, "Niclosamide-based metabolic anticancer drug candidate will be the first P53-targeting anticancer treatment that selectively kills p53 mutated cancer cells," and added, "Through our subsidiary ADM Korea, we plan to conduct clinical trials targeting cancer patients with intractable cancer caused by p53 mutations, which will be the first step of clinical development on niclosamide-based anticancer agent pipeline."
Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

Stay Connected

spot_img

About Medical Device News Magazine

About Medical Device News Magazine. A digital publication founded in 2008 located in the United States. The publication is one of the industry’s leading sources of medical device and biotech industry updates. Medical Device News Magazine is easily accessible 24/7/365 and is a fast 1, 2, 3 easy read! Our purpose is...

By using this website you agree to accept Medical Device News Magazine Privacy Policy